Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 851M 748M 695M 639M 1.2B 82.41B 1.22B 8.31B 3.24B 40.2B 3.19B 3.13B 139B P/E 2026 *
14.4x
P/E 2027 * 11x
Enterprise Value 1.16B 1.02B 949M 873M 1.64B 113B 1.67B 11.35B 4.43B 54.87B 4.36B 4.27B 190B EV / Sales 2026 *
1.56x
EV / Sales 2027 * 1.31x
Free-Float
50.29%
Yield 2026 *
-
Yield 2027 * -
1 day-1.37%
1 week-4.23%
Current month-5.75%
1 month-2.61%
3 months-9.47%
6 months-26.62%
Current year-28.98%
1 week 18.73
Extreme 18.73
20.35
1 month 18.41
Extreme 18.41
22
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
9/7/26 Free

Director

24,532 0.0556%
2/6/26 Tax

Director

-769 0.0017%
1/6/26 Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%-4.23%-15.95%-68.66% 851M
+2.01%+1.72%+48.86%+158.92% 1,037B
+1.10%+3.28%+52.67%+50.90% 615B
+0.98%+0.58%+34.27%+78.69% 448B
+5.14%+5.40%+33.75%+27.79% 326B
+1.85%+3.57%+37.09%+40.59% 293B
-0.11%+0.48%+18.87%+17.70% 264B
+0.25%-4.62%-27.66%-41.76% 216B
+0.56%-1.03%+18.93%+56.21% 198B
-0.28%-4.75%+14.33%+67.18% 162B
Average +0.99%+0.96%+21.52%+38.76% 355.83B
Weighted average by Cap. +1.53%+1.47%+35.22%+75.84%

Financials

2026 *2027 *
Net sales 746M 656M 610M 561M 1.05B 72.28B 1.07B 7.29B 2.84B 35.25B 2.8B 2.74B 122B 779M 685M 637M 586M 1.1B 75.47B 1.12B 7.61B 2.97B 36.81B 2.93B 2.86B 128B
Net income 64M 56.29M 52.29M 48.09M 90.19M 6.2B 91.81M 625M 244M 3.02B 240M 235M 10.49B 84M 73.88M 68.63M 63.12M 118M 8.13B 120M 821M 320M 3.97B 315M 309M 13.77B
Net Debt 311M 273M 254M 234M 438M 30.09B 446M 3.04B 1.18B 14.68B 1.17B 1.14B 50.92B 173M 153M 142M 130M 244M 16.79B 249M 1.69B 661M 8.19B 651M 637M 28.42B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
24/07/26 USD 19.02 -1.48% 342,861
22/07/26 USD 19.30 -1.48% 409,242
21/07/26 USD 19.59 -0.20% 621,073
20/07/26 USD 19.63 -0.58% 437,416
17/07/26 USD 19.75 -0.58% 338,457
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
19.30USD
Average target price
22.00USD
Spread / Average Target
+13.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock